Loading...
XJPX
7776
Market cap37mUSD
Jul 10, Last price  
225.00JPY
1D
1.81%
1Q
-22.68%
Jan 2017
-58.02%
IPO
-85.00%
Name

CellSeed Inc

Chart & Performance

D1W1MN
XJPX:7776 chart
P/E
P/S
74.38
EPS
Div Yield, %
Shrs. gr., 5y
19.61%
Rev. gr., 5y
-15.95%
Revenues
84m
-56.71%
275,824,000199,466,000161,673,000126,427,000190,134,000193,277,00083,678,000
Net income
-1.10b
L+28.41%
-782,398,000-783,860,000-912,871,000-759,680,000-846,534,000-859,840,000-1,104,101,000
CFO
-989m
L+14.19%
-577,000-700,678,000-817,152,000-718,006,000-779,435,000-866,104,000-988,976,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
IPO date
Mar 16, 2010
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT